DK1461318T3 - Tetrahydroquinolinanaloge som muscariniske agonister - Google Patents

Tetrahydroquinolinanaloge som muscariniske agonister

Info

Publication number
DK1461318T3
DK1461318T3 DK02794441T DK02794441T DK1461318T3 DK 1461318 T3 DK1461318 T3 DK 1461318T3 DK 02794441 T DK02794441 T DK 02794441T DK 02794441 T DK02794441 T DK 02794441T DK 1461318 T3 DK1461318 T3 DK 1461318T3
Authority
DK
Denmark
Prior art keywords
compounds
muscarinic agonists
tetrahydroquinoline
methods
muscarinic receptor
Prior art date
Application number
DK02794441T
Other languages
English (en)
Inventor
Niels Skjaerbaek
Kristian Norup Koch
Bo Lennart Mikael Friberg
Bo-Ragnar Tolf
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Application granted granted Critical
Publication of DK1461318T3 publication Critical patent/DK1461318T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK02794441T 2001-12-28 2002-12-23 Tetrahydroquinolinanaloge som muscariniske agonister DK1461318T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34472201P 2001-12-28 2001-12-28

Publications (1)

Publication Number Publication Date
DK1461318T3 true DK1461318T3 (da) 2006-01-09

Family

ID=23351729

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02794441T DK1461318T3 (da) 2001-12-28 2002-12-23 Tetrahydroquinolinanaloge som muscariniske agonister

Country Status (20)

Country Link
US (3) US7307075B2 (da)
EP (1) EP1461318B9 (da)
JP (1) JP4509565B2 (da)
KR (1) KR100972614B1 (da)
CN (1) CN100402032C (da)
AT (1) ATE304533T1 (da)
AU (1) AU2002359875B2 (da)
BR (1) BR0215430A (da)
CA (1) CA2470578C (da)
DE (1) DE60206198T2 (da)
DK (1) DK1461318T3 (da)
ES (1) ES2251624T3 (da)
HK (1) HK1074573A1 (da)
IL (2) IL162616A0 (da)
MX (1) MXPA04006281A (da)
NO (1) NO327522B1 (da)
NZ (1) NZ533566A (da)
RU (1) RU2292346C2 (da)
WO (1) WO2003057672A2 (da)
ZA (1) ZA200405024B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550459B2 (en) * 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
US7307075B2 (en) 2001-12-28 2007-12-11 Acadia Pharmaceuticals Inc. Tetrahydroquinoline analogues as muscarinic agonists
CN1777425A (zh) * 2003-03-28 2006-05-24 阿卡蒂亚药品公司 用于疼痛控制的毒蕈碱性m1受体激动剂
WO2006137485A1 (ja) * 2005-06-24 2006-12-28 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
GB0607949D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
GB0607952D0 (en) * 2006-04-21 2006-05-31 Minster Res Ltd Novel treatment
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2659412A1 (en) * 2006-07-31 2008-02-07 Janssen Pharmaceutica N.V. Urotensin ii receptor antagonists
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2011529966A (ja) 2008-08-02 2011-12-15 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ウロテンシンii受容体拮抗物質
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN106831541B (zh) 2011-11-18 2019-09-06 赫普泰雅治疗有限公司 毒蕈碱性m1受体激动剂
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
EP4447953A1 (en) 2021-12-13 2024-10-23 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3365457A (en) 1964-05-08 1968-01-23 Sterling Drug Inc N [(1-, 2-, 3-indolyl)-lower alkyl]-1, 5-iminocycloalkane and-1, 5-iminocycloalkene derivatives
US3324137A (en) 1964-05-08 1967-06-06 Sterling Drug Inc N-[indolyl-lower-alkanoyl]-1, 5-iminocycloalkanes and -iminocycloalkenes
JPS63290821A (ja) * 1987-05-25 1988-11-28 Otsuka Pharmaceut Co Ltd 抗不整脈剤
JP2886570B2 (ja) * 1989-09-29 1999-04-26 エーザイ株式会社 縮合ヘテロ環を有する化合物
US5149815A (en) * 1991-04-29 1992-09-22 American Home Products Corporation N-substituted-2-aminoquinolines
US5378698A (en) * 1991-10-21 1995-01-03 Shionogi & Co., Ltd. Benzothiazepine derivatives
US5457099A (en) * 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
DE4228095A1 (de) 1992-08-24 1994-03-03 Asta Medica Ag Neue 4,5-Dihydro-4-oxo-pyrrolo[1,2-a]chinoxaline und entsprechende Aza-analoga und Verfahren zu deren Herstellung
US5707798A (en) * 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors
TW448161B (en) * 1994-07-14 2001-08-01 Otsuka Pharma Co Ltd Cyclic amide derivatives
TR199800531T1 (xx) * 1995-09-29 1998-06-22 Glaxo Wellcome Spa NMDA antagonistleri olarak tetrahidrokinolinler.
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
EP0934932A4 (en) * 1996-08-22 2002-06-26 Meiji Seika Kaisha CHINOLINE DERIVATIVES AND PSYCHOTROPES MEDIUM
US5919750A (en) * 1997-07-24 1999-07-06 Akzo Nobel Nv Fabric softener composition
KR20010042296A (ko) * 1998-03-31 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세린 프로테아제 억제제로서의 벤즈옥사지논/벤조티아지논
JP2002509918A (ja) * 1998-03-31 2002-04-02 アケイディア ファーマスーティカルズ インコーポレイテッド ムスカリン性レセプタに活性を有する化合物
ATE275141T1 (de) * 1999-10-13 2004-09-15 Banyu Pharma Co Ltd Substituierte imidazolin-derivate
SK11072002A3 (sk) * 1999-12-30 2003-03-04 H. Lundbeck A/S Halogénom substituované 4-fenyl-1-piperazinylové, -piperidinylové a -tetrahydropyridylové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
WO2001064670A1 (fr) * 2000-02-29 2001-09-07 Mitsubishi Pharma Corporation Nouveaux derives amide cycliques
RU2269523C2 (ru) * 2000-04-28 2006-02-10 Акадиа Фармасьютикалз, Инк. Мускариновые агонисты
US6951849B2 (en) 2001-10-02 2005-10-04 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
US7307075B2 (en) 2001-12-28 2007-12-11 Acadia Pharmaceuticals Inc. Tetrahydroquinoline analogues as muscarinic agonists
CN1777425A (zh) 2003-03-28 2006-05-24 阿卡蒂亚药品公司 用于疼痛控制的毒蕈碱性m1受体激动剂

Also Published As

Publication number Publication date
IL162616A0 (en) 2005-11-20
NO20043013L (no) 2004-07-28
EP1461318A2 (en) 2004-09-29
ZA200405024B (en) 2005-07-27
KR100972614B1 (ko) 2010-07-27
HK1074573A1 (en) 2005-11-18
RU2004123203A (ru) 2006-01-20
DE60206198T2 (de) 2006-06-14
US20060199813A1 (en) 2006-09-07
US20060199810A1 (en) 2006-09-07
EP1461318B9 (en) 2005-12-28
AU2002359875A1 (en) 2003-07-24
MXPA04006281A (es) 2004-09-27
CN100402032C (zh) 2008-07-16
WO2003057672A3 (en) 2003-11-13
EP1461318B1 (en) 2005-09-14
RU2292346C2 (ru) 2007-01-27
CN1635891A (zh) 2005-07-06
JP2005519060A (ja) 2005-06-30
AU2002359875B2 (en) 2009-01-08
US7576100B2 (en) 2009-08-18
US7576078B2 (en) 2009-08-18
US20030176418A1 (en) 2003-09-18
DE60206198D1 (de) 2005-10-20
IL162616A (en) 2011-06-30
ATE304533T1 (de) 2005-09-15
JP4509565B2 (ja) 2010-07-21
NO327522B1 (no) 2009-08-03
NZ533566A (en) 2007-03-30
WO2003057672A2 (en) 2003-07-17
ES2251624T3 (es) 2006-05-01
US7307075B2 (en) 2007-12-11
CA2470578A1 (en) 2003-07-17
CA2470578C (en) 2010-10-12
BR0215430A (pt) 2004-12-14
KR20040070287A (ko) 2004-08-06

Similar Documents

Publication Publication Date Title
DK1461318T3 (da) Tetrahydroquinolinanaloge som muscariniske agonister
TW200634006A (en) Tetrahydroquinoline analogues as muscarinic agonists
NO20042964L (no) Spiroazasykliske forbindelser som monoaminreseptormodulatorer
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
DE69926806D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
BR0317110A (pt) Tratamento de doenças com combinações de agonistas do receptor nicotìnico da acetilcolina alfa 7 e outros compostos
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
UY26130A1 (es) Compuestos para tratar la obesidad
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
EA200100780A1 (ru) Антагонисты tweak и рецептора tweak и их использование для лечения иммунологических заболеваний
MA27933A1 (fr) Inhibiteurs de l&#39;activite de akt
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
ES2328496T3 (es) Compuestos de 1,4,8-triaza-espiro(4,5)decan-2-ona sustituidos.
EA200500803A1 (ru) Антагонисты ccr1 для лечения воспалительных артритов, демиелинизационных воспалительных заболеваний
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
DE60329326D1 (de) Tace inhibitoren
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
EA200500045A1 (ru) Новые соединения, их применение и получение
ATE274515T1 (de) Pyrazolopyridinderivate
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
TNSN08275A1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
BR0317377A (pt) Derivados de 5-aminofenantridina como antagonistas de npy-5